Matrix Partners China and Efung Capital led a CNY890m (approximately USD135m) Series E for Beijing Biostar Technologies, a China-based developer of anti-tumor, small-molecule chemical drugs, with participation from CCB International Capital, Sinopharma-CICC Capital, Tianjin Venture Capital Management, and Chengdu Tianfu International Bio-Town Investment & Development. Read more